Esperion Therapeutics (ESPR) 25th Annual Needham Virtual Healthcare Conference summary

Business performance and strategic vision

• Achieved 38% year-over-year revenue growth and 34% growth in TRPEs, with strong international launches, notably in Japan since November.

• Outlined Vision 2040, focusing on maximizing the bempedoic acid franchise, business development, and pipeline expansion.

• Closed the acquisition of Corstasis Therapeutics, adding Enbumyst for heart failure to the portfolio.

• Aims to achieve profitability within the current year, marking a significant milestone.

• Emphasized ongoing execution and growth, with a robust infrastructure supporting commercial and pipeline activities.

Corstasis Therapeutics acquisition and Enbumyst launch

• Enbumyst, a nasal spray loop diuretic for heart failure, addresses high hospital readmission rates and enables at-home treatment.

• Product approved in September 2025; full commercial launch with 155+ sales reps planned for September, with initial field presence by May 1.

• Acquisition terms: $75 million upfront, $180 million in sales-based milestones, and 15% royalty on net sales.

• Financing supported by monetizing Japanese royalties and expanding a term loan facility.

• Plans to develop an auto-injector version, with FDA discussions scheduled and potential launch around 2028.

Commercialization, access, and reimbursement

• Enbumyst targets outpatient use, with a payer mix leaning toward Medicare due to the older patient population.

• Corstasis laid groundwork with 10 field reps; expanded commercial team and payer engagement underway.

• Strong access and reimbursement team leveraging experience from bempedoic acid franchise.

• Budget impact model and economic data to be presented at a major heart failure conference in June.